The people at highest risk are the ones left out.
Em um país que registrou mais de mil mortes por dengue em 2023 e responde por mais da metade dos casos globais, uma vacina eficaz chegou ao mercado — mas o acesso a ela revela as fraturas antigas de um sistema de saúde dividido entre quem pode pagar e quem precisa esperar. A Qdenga, aprovada para pessoas de 4 a 60 anos, está disponível em clínicas privadas por valores que equivalem a um salário mínimo para muitos brasileiros, enquanto o SUS inicia uma distribuição restrita por escassez de doses. A chegada de uma ferramenta poderosa nem sempre significa que ela chegará a quem mais precisa.
- O Brasil atravessa o verão — estação do Aedes aegypti — carregando o peso do pior ano de dengue já registrado, com 1.094 mortes confirmadas em 2023.
- A demanda pela Qdenga disparou entre 50% e 160% em diferentes regiões em janeiro, impulsionada pelo medo da escassez no sistema público e pela chegada da temporada de transmissão.
- O curso completo da vacina custa entre R$780 e R$980 em clínicas privadas, valor inacessível para grande parte da população que dependeria do SUS — onde as doses serão inicialmente restritas a jovens de 6 a 16 anos.
- Especialistas alertam que a vacinação privada, inferior a 10% da população, protege indivíduos mas não altera o quadro epidemiológico coletivo.
- Idosos acima de 60 anos — os mais vulneráveis às formas graves da doença — permanecem fora da faixa aprovada, criando um vazio de proteção justamente onde o risco é maior.
A Qdenga, vacina contra a dengue desenvolvida pela farmacêutica japonesa Takeda, chegou ao Brasil em julho de 2023 com uma promessa inédita: proteger tanto quem nunca teve a doença quanto quem já foi infectado, para pessoas entre 4 e 60 anos. Seis meses depois, ela está disponível em clínicas privadas por entre R$390 e R$490 por dose — e, como o esquema exige duas aplicações com três meses de intervalo, o curso completo pode custar quase um salário mínimo.
O país que mais precisa da vacina é também o que encontra mais dificuldade em acessá-la. Em 2023, o Brasil bateu seu próprio recorde de mortes por dengue, com 1.094 óbitos confirmados, e foi apontado pela OMS como epicentro global da doença. Ainda assim, a procura pela vacina nas clínicas privadas só começou a crescer com a chegada do verão e o anúncio da incorporação ao SUS — que, por escassez de doses, limitará a distribuição pública a jovens de 6 a 16 anos.
A eficácia da Qdenga é robusta: 80,2% de proteção contra infecção e 90,4% contra casos graves nos ensaios clínicos. Especialistas recomendam a vacina especialmente para quem já teve dengue — uma segunda infecção por cepa diferente tende a ser mais severa — e para regiões como o Centro-Oeste e o Sul, onde a doença avança sobre populações sem imunidade prévia.
Há, porém, restrições importantes. Por ser uma vacina de vírus vivo atenuado, é contraindicada para grávidas, imunossuprimidos e alérgicos aos componentes. E o limite de idade em 60 anos deixa os idosos — justamente os mais vulneráveis — sem cobertura oficial.
O preço varia por clínica e região, e muitas cobram taxas adicionais de consulta e aconselhamento além do valor da dose. O que se desenha é um retrato familiar: uma ferramenta médica eficaz, uma necessidade urgente e um acesso profundamente desigual — disponível para quem pode pagar, racionado no sistema público, inexistente para os mais velhos.
Brazil's newest weapon against dengue arrived quietly last summer. The Qdenga vaccine, made by Japanese pharmaceutical company Takeda, hit the market in July 2023 as the first shot capable of protecting everyone from age four to sixty—whether they'd never caught the virus or had already been infected. Six months later, the vaccine sits in private clinics across the country at a price that puts it out of reach for most: between 390 and 490 reais per dose. Since the regimen requires two injections spaced three months apart, the full course runs 780 to 980 reais. That's roughly equivalent to a month's wages for many Brazilians.
Demand has been modest, even as the country reels from a historic year. In 2023, Brazil recorded 1,094 confirmed dengue deaths—the highest toll on record—and the World Health Organization identified the nation as the epicenter of the global outbreak, accounting for more than half of all cases worldwide. Yet the vaccine has not sparked the rush one might expect. Demand is climbing, though. At Richet Vacina, a vaccination clinic in Rio de Janeiro, applications jumped 50 percent in January compared to December. The Dasa health network saw an even steeper rise: more than 70 percent between mid-January and December, with some regions reporting far sharper increases. In the Center-West, where dengue ravaged communities last year, demand surged past 160 percent.
The timing matters. Summer is dengue season in Brazil—the warm months when the Aedes mosquito thrives and transmission accelerates. The government's announcement that the vaccine would enter the public health system also drove people to private clinics, worried that free doses would be scarce. And they were right to worry. The SUS will initially offer Qdenga only to specific groups of young people between six and sixteen, a restriction imposed by limited supply. The private sector operates under different logic. "In private clinics, we aim for individual protection," explains José Geraldo Leite Ribeiro, an epidemiologist at Grupo Fleury and professor at the Federal University of Minas Gerais. "The percentage of people vaccinated privately isn't enough to shift case numbers—it's less than ten percent of the population—but it protects that person."
The vaccine itself is formidable. Clinical trials showed it prevented infection in 80.2 percent of cases overall and severe disease in 90.4 percent. The Brazilian Society of Immunizations recommends it for everyone in the approved age range, infected or not. Rosana Richtmann, director of the immunization committee at the Brazilian Society of Infectology, notes that people who've already had dengue benefit especially; a second infection with a different strain tends to be worse. She considers geography too. The South, which had virtually no dengue before, is now facing an epidemic among a population with no experience managing the virus. The Center-West, where cases exploded last year, is another priority zone.
But the vaccine comes with real constraints. It's a live attenuated vaccine—made from weakened virus—which means it's off-limits for pregnant women, nursing mothers, people with compromised immune systems, and anyone allergic to its components. Those taking immunosuppressive medications must wait four weeks after stopping treatment. The vaccine is approved only through age sixty, leaving older adults, who suffer the most severe cases, without protection. Some doctors recommend it off-label to patients over sixty, but officially the age cap stands.
Price varies by clinic and region. At Fleury's network of labs and clinics, which operates across twelve states and the federal district, doses range from 400 to 490 reais depending on location. Richet charges 450 reais per dose at its Rio units and offers home visits. Labi clinics in Rio and São Paulo undercut the market at 390 reais. The Dasa network, which encompasses thirty brands across twelve states, did not disclose its pricing. The Brazilian regulatory agency sets a maximum consumer price between 346 and 390 reais per dose, but clinics add fees for medical consultation, vaccination record review, and pre- and post-vaccination counseling. Most clinics no longer require a prior prescription, though the vaccine technically demands one; many vaccination centers have in-house doctors who can screen patients on the spot.
What emerges is a portrait of a country with a tool it cannot yet fully deploy. The vaccine works. The need is urgent. But access remains fractured—available to those who can pay, rationed in the public system, absent entirely for the elderly who face the gravest risk. As summer deepens and mosquitoes multiply, the gap between what medicine can offer and what the health system can deliver grows wider.
Notable Quotes
In private clinics, we aim for individual protection. The percentage of people vaccinated privately isn't enough to shift case numbers—it's less than ten percent of the population—but it protects that person.— José Geraldo Leite Ribeiro, epidemiologist at Grupo Fleury
The South is now facing an epidemic among a population with no experience managing the virus.— Rosana Richtmann, director of immunization committee at Brazilian Society of Infectology
The Hearth Conversation Another angle on the story
Why hasn't demand been higher, given that Brazil just had its deadliest dengue year on record?
Part of it is simple awareness. The vaccine only arrived last summer. But there's also a cost barrier—780 to 980 reais for the full course is significant for most Brazilians. And there's uncertainty. People are waiting to see if the public system will offer it free, which creates a kind of hesitation in the private market.
The government is putting it in the SUS, though. Why the rationing?
Supply. There aren't enough doses yet. So they're limiting it to specific age groups—young people between six and sixteen—to stretch what they have. That's actually why demand in private clinics spiked when the announcement came. People realized free access would be restricted and rushed to pay for it themselves.
But the data shows most severe cases happen in people over sixty. Why aren't they eligible?
That's the painful contradiction. The vaccine was only tested and approved for ages four to sixty in Brazil. Some doctors recommend it off-label to older patients, but officially the age cap is firm. So the people at highest risk are the ones left out.
Is the vaccine actually effective?
Very. Clinical trials showed 80 percent efficacy against infection overall, and 90 percent against severe disease. It works for people who've never had dengue and for those who've been infected before—maybe even better for the latter group, since a second infection with a different strain tends to be worse.
What are the real contraindications?
It's a live vaccine, so pregnant women and nursing mothers can't take it. Anyone with a compromised immune system is out. People on immunosuppressive drugs have to wait four weeks after stopping. And anyone with an allergy to the vaccine's components—there's a long list of them—needs to avoid it. But for a healthy person in the approved age range, it's generally safe.
So who's actually getting vaccinated?
Mostly adults in the private sector who can afford it and are worried about dengue. Demand jumped 50 to 160 percent in January as summer arrived and the SUS announcement came through. But we're still talking about less than ten percent of the population in private clinics. It's individual protection, not population-level control.